Kadmon Holdings Llc (KDMN) Stock Price & Overview
NASDAQ:KDMN
Current stock price
The current stock price of KDMN is 9.5 null. Today KDMN is up by 0.21%. In the past month the price increased by 5.67%. In the past year, price increased by 174.57%.
KDMN Key Statistics
- Market Cap
- 1.634B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.67
- Dividend Yield
- N/A
KDMN Stock Performance
KDMN Stock Chart
KDMN Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to KDMN. When comparing the yearly performance of all stocks, KDMN is one of the better performing stocks in the market, outperforming 97.65% of all stocks.
KDMN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KDMN. Both the profitability and financial health of KDMN have multiple concerns.
KDMN Earnings
KDMN Forecast & Estimates
12 analysts have analysed KDMN and the average price target is 12.34 null. This implies a price increase of 29.92% is expected in the next year compared to the current price of 9.5.
For the next year, analysts expect an EPS growth of -11.43% and a revenue growth -3.81% for KDMN
KDMN Groups
Sector & Classification
KDMN Financial Highlights
Over the last trailing twelve months KDMN reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS increased by 28.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -5955.81% | ||
| ROA | -35.84% | ||
| ROE | N/A | ||
| Debt/Equity | 6.96 |
KDMN Ownership
KDMN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.808B | ||
| AMGN | AMGEN INC | 15.1 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.53 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KDMN
Company Profile
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company is headquartered in New York City, New York. The company went IPO on 2016-07-27. The firm's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The company is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The firm has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.
Company Info
IPO: 2016-07-27
Kadmon Holdings Llc
450 E 29th St
New York City NEW YORK 10016 US
CEO: Harlan W. Waksal
Employees: 0
Phone: 18339005366.0
Kadmon Holdings Llc / KDMN FAQ
What does Kadmon Holdings Llc do?
Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company is headquartered in New York City, New York. The company went IPO on 2016-07-27. The firm's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The company is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The firm has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.
Can you provide the latest stock price for Kadmon Holdings Llc?
The current stock price of KDMN is 9.5 null. The price increased by 0.21% in the last trading session.
Does Kadmon Holdings Llc pay dividends?
KDMN does not pay a dividend.
What is the ChartMill rating of Kadmon Holdings Llc stock?
KDMN has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for KDMN stock?
Kadmon Holdings Llc (KDMN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
Is Kadmon Holdings Llc (KDMN) expected to grow?
The Revenue of Kadmon Holdings Llc (KDMN) is expected to decline by -3.81% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of KDMN stock?
Kadmon Holdings Llc (KDMN) has a market capitalization of 1.63B null. This makes KDMN a Small Cap stock.